What is Sidoti’s Forecast for LGL Group Q1 Earnings?

LGL Group, Inc. (The) (NYSEAMERICAN:LGL) – Equities researchers at Sidoti issued their Q1 2026 EPS estimates for shares of LGL Group in a note issued to investors on Thursday, May 7th. Sidoti analyst A. Soderstrom forecasts that the industrial products company will earn $0.01 per share for the quarter. Sidoti also issued estimates for LGL Group’s Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at $0.06 EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.03 EPS and FY2027 earnings at $0.07 EPS.

LGL Group Stock Up 2.6%

Shares of NYSEAMERICAN LGL opened at $7.15 on Friday. The firm’s 50-day moving average price is $7.14 and its 200-day moving average price is $6.58. The company has a market cap of $46.76 million, a PE ratio of 65.00 and a beta of 0.31. LGL Group has a 52-week low of $5.45 and a 52-week high of $9.74.

LGL Group (NYSEAMERICAN:LGL) last announced its quarterly earnings data on Monday, March 30th. The industrial products company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.09). The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.62%.

Hedge Funds Weigh In On LGL Group

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC bought a new position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group at the end of the most recent quarter. Institutional investors own 30.28% of the company’s stock.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.